Blog

  • 3 trends shaping the future of Biomanufacturing

    3 trends shaping the future of Biomanufacturing

    Expert Marius Müller, PhD, Team Lead at Johnson & Johnson Innovative Medicine, shares insights into three significant trends that have potential to reshape the biopharma and biomanufacturing industry

    Read
  • Boost Your Lab's Performance: 3 Ways to Increase Efficiency with Prometheus Panta

    Boost Your Lab's Performance: 3 Ways to Increase Efficiency with Prometheus Panta

    Learn how to enhance your lab's efficiency with Prometheus Panta, from using capillary chips for high-throughput sample loading to solutions for seamless integration in automated workflows

    Read
  • Pushing Boundaries in Biophysics and Biomanufacturing

    Pushing Boundaries in Biophysics and Biomanufacturing

    Marius, a biophysics expert at Johnson & Johnson Innovative Medicine, shares his insights into this rapidly evolving field of biomanufacturing.

    Read
  • 5 biologics conferences you won’t want to miss in 2025

    5 biologics conferences you won’t want to miss in 2025

    Use this curated list of must-attend 2025 biologics conferences to plan your year. Find out when and where each conference takes place, who will be there, and what you can expect.

    Read
  • NanoTemper Announces Leadership Evolution: Philipp Baaske Transitions to Executive Chairman

    NanoTemper Announces Leadership Evolution: Philipp Baaske Transitions to Executive Chairman

    NanoTemper Technologies is entering a new chapter of leadership. After 16 years as Co-CEOs, Philipp Baaske and Stefan Duhr have redefined their roles to better position the company for continued growt

    Read
  • ×

    Sign up to receive
    the latest NanoTemper news, product updates, event announcements and more

    First Name
    Last Name
    Company Name
    Country
    State
    Province
    State
    Region
    State
    Canton
    Agree to Subscribe & Privacy Policy*
    *I have fully read, understood and agree to the Privacy Policy. I accept the storing and processing of my personal data by NanoTemper as described in the Privacy Policy.

    By completing this form, you provide us consent to contact you with educational content, news and information about our products, services and events. You may unsubscribe at any time.
    Thank you!
    Error - something went wrong!
  • NanoTemper Technologies unveils Dianthus uHTS — the fastest biophysical method on the market

    NanoTemper Technologies unveils Dianthus uHTS — the fastest biophysical method on the market

    NanoTemper Technologies has established an advisory board consisting of five distinguished professionals, each a seasoned expert in their respective fields. This move underscores NanoTemper...

    Read
  • NanoTemper Technologies Establishes Advisory Board to Propel Innovation and Growth

    NanoTemper Technologies Establishes Advisory Board to Propel Innovation and Growth

    NanoTemper Technologies has established an advisory board consisting of five distinguished professionals, each a seasoned expert in their respective fields. This move underscores NanoTemper...

    Read
  • 5 considerations for buffer optimization during biologics pre-formulation

    5 considerations for buffer optimization during biologics pre-formulation

    The work of pre-formulations scientists is critical to de-risk the entire development process for biologics. Read on to learn more about what to consider about your buffer components for...

    Read
  • 5 types of formulation excipients and how they impact biologics stability

    5 types of formulation excipients and how they impact biologics stability

    Each excipient class helps stabilize biologics – from monoclonal antibodies to vaccine antigens – in different ways. Read on to learn more about some of the most important excipients for...

    Read
  • Contact Specialist
  • NanoTemper brings Spectral Shift technology to the protein production market with Andromeda X, enabling biopharma and CROs

    NanoTemper brings Spectral Shift technology to the protein production market with Andromeda X, enabling biopharma and CROs

    NanoTemper Technologies, well known for creating biophysical tools that accelerate the work of drug discovery researchers, brings their groundbreaking Spectral Shift technology to the protein...

    Read
  • Three things we took away from attending Drug Discovery Chemistry in 2024

    Three things we took away from attending Drug Discovery Chemistry in 2024

    Drug Discovery Chemistry is an annual event that focuses solely on early drug discovery, where scientists from around the world gather to showcase their research and participate in thoughtful...

    Read
  • Get predictive insight into your ADC’s stability with these 3 experiments

    Get predictive insight into your ADC’s stability with these 3 experiments

    Learn how it’s possible to use the Prometheus Panta to extrapolate how your low concentration sample will behave once it’s scaled up and at higher concentrations used for clinical administration.

    Read
  • 5 biologics conferences you won’t want to miss in 2024

    5 biologics conferences you won’t want to miss in 2024

    Use this list of crowd-sourced favorites to kick-start your 2024 biologics conference plans. Find out when and where each conference takes place, who will be there, which topics are covered, and...

    Read
  • Attend these targeted protein degradation conferences in 2024 to stay in the know

    Attend these targeted protein degradation conferences in 2024 to stay in the know

    Attending dedicated targeted protein degradation conferences and tracks is a great way to keep up with this rapidly evolving field. Here are 8 conferences you’ll want to attend in 2024.

    Read
  • De-risk your ADC development process with these stability considerations

    De-risk your ADC development process with these stability considerations

    Antibody-drug conjugates, or ADCs, are revolutionary therapeutics that represent a growing proportion of the biologics market. They combine the targeting power of a monoclonal antibody, which is...

    Read
  • How stability characterization parameters help you create biologics developability profiles

    How stability characterization parameters help you create biologics developability profiles

    Developability profiles help you avoid risk by collecting many quality attributes associated with each candidate, enabling you to rank each candidate by the most optimal attributes and make a...

    Read
  • How to predict your biologics candidates' behavior at high concentrations with light-scattering techniques

    How to predict your biologics candidates' behavior at high concentrations with light-scattering techniques

    Light scattering techniques are used to predict high-concentration behavior of candidates early in the development process. Let's take a look at what they tell you, how to set them up, and how...

    Read
  • What to consider when adding DLS to your early biologics development workflow

    What to consider when adding DLS to your early biologics development workflow

    Read on to find the answers to questions your early development scientist peers have asked about how to use DLS to design, select, and advance the most stable biologics candidates.

    Read
  • How early discovery and development teams use DLS to de⁠-⁠risk downstream biologics development

    How early discovery and development teams use DLS to de⁠-⁠risk downstream biologics development

    As a discovery or early development scientist, you’re tasked with identifying the most promising biologics candidates. Your hard work during early development enables straightforward and efficient...

    Read
  • 8 Targeted Protein Degradation conferences in 2023 you won’t want to miss

    8 Targeted Protein Degradation conferences in 2023 you won’t want to miss

    2023 is expected to be a year of big announcements in the targeted protein degradation (TPD) therapeutics space. With more than 20 degraders in clinical trials, many decisions are coming. The race...

    Read
  • loading
    Loading more...